245 related articles for article (PubMed ID: 2452737)
1. Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction.
Poulos A; Sharp P; Fellenberg AJ; Johnson DW
Eur J Pediatr; 1988 Feb; 147(2):143-7. PubMed ID: 2452737
[TBL] [Abstract][Full Text] [Related]
2. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.
Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR
J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705
[TBL] [Abstract][Full Text] [Related]
3. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders.
ten Brink HJ; Schor DS; Kok RM; Poll-The BT; Wanders RJ; Jakobs C
J Lipid Res; 1992 Oct; 33(10):1449-57. PubMed ID: 1385561
[TBL] [Abstract][Full Text] [Related]
4. Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
Ferdinandusse S; Rusch H; van Lint AE; Dacremont G; Wanders RJ; Vreken P
J Lipid Res; 2002 Mar; 43(3):438-44. PubMed ID: 11893780
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of phytanic acid and pristanic acid in man: a review.
Verhoeven NM; Wanders RJ; Poll-The BT; Saudubray JM; Jakobs C
J Inherit Metab Dis; 1998 Oct; 21(7):697-728. PubMed ID: 9819701
[TBL] [Abstract][Full Text] [Related]
6. Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders.
Herzog K; van Lenthe H; Wanders RJA; Vaz FM; Waterham HR; Ferdinandusse S
Mol Genet Metab; 2017 Jul; 121(3):279-282. PubMed ID: 28566232
[TBL] [Abstract][Full Text] [Related]
7. Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography.
ten Brink HJ; Stellaard F; van den Heuvel CM; Kok RM; Schor DS; Wanders RJ; Jakobs C
J Lipid Res; 1992 Jan; 33(1):41-7. PubMed ID: 1372637
[TBL] [Abstract][Full Text] [Related]
8. Phytanic acid oxidation: normal activation and transport yet defective alpha-hydroxylation of phytanic acid in peroxisomes from Refsum disease and rhizomelic chondrodysplasia punctata.
Pahan K; Khan M; Singh I
J Lipid Res; 1996 May; 37(5):1137-43. PubMed ID: 8725164
[TBL] [Abstract][Full Text] [Related]
9. Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders.
Kase BF; Björkhem I
Scand J Clin Lab Invest; 1996 May; 56(3):211-7. PubMed ID: 8761525
[TBL] [Abstract][Full Text] [Related]
10. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.
Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM
Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966
[TBL] [Abstract][Full Text] [Related]
11. Phytanic acid alpha-oxidation in peroxisomal disorders: studies in cultured human fibroblasts.
Verhoeven NM; Schor DS; Roe CR; Wanders RJ; Jakobs C
Biochim Biophys Acta; 1997 Oct; 1361(3):281-6. PubMed ID: 9375802
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of peroxisomal disorders by analysis of phytanic and pristanic acids in stored blood spots collected at neonatal screening.
ten Brink HJ; van den Heuvel CM; Christensen E; Largillière C; Jakobs C
Clin Chem; 1993 Sep; 39(9):1904-6. PubMed ID: 8375069
[TBL] [Abstract][Full Text] [Related]
13. The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders.
Van Veldhoven PP; Huang S; Eyssen HJ; Mannaerts GP
J Inherit Metab Dis; 1993; 16(2):381-91. PubMed ID: 7692128
[TBL] [Abstract][Full Text] [Related]
14. An improved method for quantification of very long chain fatty acids in plasma.
Vallance H; Applegarth D
Clin Biochem; 1994 Jun; 27(3):183-6. PubMed ID: 7522996
[TBL] [Abstract][Full Text] [Related]
15. [Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers].
Molzer B; Stöckler S; Bernheimer H
Wien Klin Wochenschr; 1992; 104(21):665-70. PubMed ID: 1282286
[TBL] [Abstract][Full Text] [Related]
16. Human metabolism of phytanic acid and pristanic acid.
Verhoeven NM; Jakobs C
Prog Lipid Res; 2001 Nov; 40(6):453-66. PubMed ID: 11591435
[TBL] [Abstract][Full Text] [Related]
17. Disorders related to the metabolism of phytanic acid.
Stokke O; Skjeldal OH; Høie K
Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746
[TBL] [Abstract][Full Text] [Related]
18. Pristanic acid and phytanic acid in plasma from patients with a single peroxisomal enzyme deficiency.
ten Brink HJ; Wanders RJ; Stellaard F; Schutgens RB; Jakobs C
J Inherit Metab Dis; 1991; 14(3):345-8. PubMed ID: 1722861
[No Abstract] [Full Text] [Related]
19. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes.
Singh I; Pahan K; Singh AK; Barbosa E
J Lipid Res; 1993 Oct; 34(10):1755-64. PubMed ID: 7504046
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation.
Skjeldal OH; Stokke O; Refsum S; Norseth J; Petit H
J Neurol Sci; 1987 Jan; 77(1):87-96. PubMed ID: 2433405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
